SCHEMBL4280084

SCHEMBL4280084

NC1=NC(c2ccccc2)=CC(N)(c2ccc(Cl)cc2)N1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.35
LMNA P02545 3/20 0.33
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
HPGD P15428 1/20 0.33
KDM1A O60341 1/20 0.33
RCOR1 Q9UKL0 1/20 0.33
CTSD P07339 1/20 0.33
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
MECP2 P51608 1/20 0.33
MBD2 Q9UBB5 1/20 0.33
MAP4K4 O95819 1/20 0.33
MAPT P10636 2/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
APAF1 O14727 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287050 0.74 AGPAT2 (0.33) CYP1A2KDM4EALDH1A1HPGDMAPT
SCHEMBL4282527 0.71 HSP90AA1 (0.34) CYP1A2LMNAKDM4EHPGDMAPT
SCHEMBL4284234 0.68 AGPAT2 (0.34) CYP1A2KDM4EALDH1A1MAPTL3MBTL1
SCHEMBL4280081 0.68 CYP1A2 (0.37) CYP1A2LMNAKDM4ESMN1; SMN2KDM1A
SCHEMBL2323806 0.67 CYP1A2 (0.36) CYP1A2LMNAKDM4ESMN1; SMN2ALDH1A1
Biphenyl SCHEMBL10833965 0.59 CYP1A2 (0.81) CYP1A2LMNAKDM4ESMN1; SMN2ALDH1A1
Biphenyl SCHEMBL27859632 0.59 CYP1A2 (0.93) CYP1A2LMNAKDM4ESMN1; SMN2ALDH1A1
1,4-Dichlorobenzene SCHEMBL9297848 0.59 TSHR (0.92) CYP1A2LMNAKDM4EMAPTGAA
SCHEMBL183912 0.57 CYP1A2 (1.00) CYP1A2LMNAKDM4ESMN1; SMN2ALDH1A1
Biphenyl SCHEMBL27505710 0.57 CYP1A2 (0.77) CYP1A2LMNAKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT CYP1A2 4325/4885LMNA 1834/4885KDM4E 1842/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT CYP1A2 4519/4885LMNA 1671/4885KDM4E 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.